
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
The Thermo Scientific Vanquish Duo system for Dual employs two separate flow paths for simultaneous analysis of complex samples.






